Cargando…

Synergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells

In our preliminary study, Berbamine (BA), one of the most commonly used traditional Chinese medicines, was effective in inducing the intracellular ROS levels. Since the regulation of cellular antioxidant capacity is crucial to the sensitivity of Ptx, it is feasible to propose that sensitizing cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Feng, Ruan, Shu, Liu, Ning, Fu, Linshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572090/
https://www.ncbi.nlm.nih.gov/pubmed/28883885
http://dx.doi.org/10.1155/2017/8152526
_version_ 1783259466716676096
author Jia, Feng
Ruan, Shu
Liu, Ning
Fu, Linshan
author_facet Jia, Feng
Ruan, Shu
Liu, Ning
Fu, Linshan
author_sort Jia, Feng
collection PubMed
description In our preliminary study, Berbamine (BA), one of the most commonly used traditional Chinese medicines, was effective in inducing the intracellular ROS levels. Since the regulation of cellular antioxidant capacity is crucial to the sensitivity of Ptx, it is feasible to propose that sensitizing cells to Ptx can be achieved through increasing the antioxidant capacity by codelivering BA. Cytotoxicity test demonstrates that either single or combinational treatment of BA and Ptx dose-dependently inhibits the proliferation of U-87 cells. Median-effect analysis clearly proves the synergistic anticancer effect between BA and Ptx. Combinational treatment of both drugs induced more intracellular ROS generation than either of the drugs did. Cotreatment of NAC could partially reverse the ROS generation and ameliorate the cytotoxicity induced by BA plus Ptx. Moreover, sequential activation of ROS-dependent phosphor-Akt expression was dose-dependently inhibited by the combinational application of BA and Ptx, which was more significantly effective than the single treatment of either BA or Ptx. Additionally, the coadministration of BA and Ptx shows the strongest tumor delaying effect in a U87 xenograft model, demonstrating the synergism between two drugs. Therefore, BA is a promising adjuvant to traditional chemotherapy, especially in combination with Ptx, to treat malignant glioma.
format Online
Article
Text
id pubmed-5572090
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-55720902017-09-07 Synergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells Jia, Feng Ruan, Shu Liu, Ning Fu, Linshan Evid Based Complement Alternat Med Research Article In our preliminary study, Berbamine (BA), one of the most commonly used traditional Chinese medicines, was effective in inducing the intracellular ROS levels. Since the regulation of cellular antioxidant capacity is crucial to the sensitivity of Ptx, it is feasible to propose that sensitizing cells to Ptx can be achieved through increasing the antioxidant capacity by codelivering BA. Cytotoxicity test demonstrates that either single or combinational treatment of BA and Ptx dose-dependently inhibits the proliferation of U-87 cells. Median-effect analysis clearly proves the synergistic anticancer effect between BA and Ptx. Combinational treatment of both drugs induced more intracellular ROS generation than either of the drugs did. Cotreatment of NAC could partially reverse the ROS generation and ameliorate the cytotoxicity induced by BA plus Ptx. Moreover, sequential activation of ROS-dependent phosphor-Akt expression was dose-dependently inhibited by the combinational application of BA and Ptx, which was more significantly effective than the single treatment of either BA or Ptx. Additionally, the coadministration of BA and Ptx shows the strongest tumor delaying effect in a U87 xenograft model, demonstrating the synergism between two drugs. Therefore, BA is a promising adjuvant to traditional chemotherapy, especially in combination with Ptx, to treat malignant glioma. Hindawi 2017 2017-08-13 /pmc/articles/PMC5572090/ /pubmed/28883885 http://dx.doi.org/10.1155/2017/8152526 Text en Copyright © 2017 Feng Jia et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jia, Feng
Ruan, Shu
Liu, Ning
Fu, Linshan
Synergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells
title Synergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells
title_full Synergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells
title_fullStr Synergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells
title_full_unstemmed Synergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells
title_short Synergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells
title_sort synergistic antitumor effects of berbamine and paclitaxel through ros/akt pathway in glioma cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572090/
https://www.ncbi.nlm.nih.gov/pubmed/28883885
http://dx.doi.org/10.1155/2017/8152526
work_keys_str_mv AT jiafeng synergisticantitumoreffectsofberbamineandpaclitaxelthroughrosaktpathwayingliomacells
AT ruanshu synergisticantitumoreffectsofberbamineandpaclitaxelthroughrosaktpathwayingliomacells
AT liuning synergisticantitumoreffectsofberbamineandpaclitaxelthroughrosaktpathwayingliomacells
AT fulinshan synergisticantitumoreffectsofberbamineandpaclitaxelthroughrosaktpathwayingliomacells